Tonix Pharmaceuticals reported second quarter 2026 net product revenue of approximately $13.5 million, driven by $11 million in net sales of its fibromyalgia drug TONMYA, a 197% quarter-over-quarter increase. The company also announced it is expanding its sales force by 50 representatives to roughly 150 by September, and that TONMYA now covers approximately 136 million lives, or 43% of covered lives in the United States. Tonix advanced its pipeline, randomizing the first patient in a Phase II study of TNX-102 SL for major depressive disorder and receiving positive FDA meeting minutes for a planned adaptive Phase II study of TNX-4800 for Lyme disease prevention, with enrollment expected in the first quarter of 2027. The company ended the quarter with $176.2 million in cash and cash equivalents, and expects its resources to fund operations into early second quarter of 2027.
Tonix Pharmaceuticals Holding CorpTONMYA sales tripled quarter-over-quarter, indicating strong end-customer demand for the fibromyalgia drug.
